Assertio Holdings, Inc. (ASRT)
Assertio Holdings, Inc. is a specialty pharmaceutical company focused on neurology, hospital, and pain and inflammation medications. They develop and market treatments for conditions like rheumatoid arthritis, migraines, and acute pain.
Company Overview
Assertio Holdings, Inc. (ASRT) is a specialty pharmaceutical company revitalizing established neurology, hospital, and pain & inflammation medications, offering investors a unique opportunity in a niche market with a focus on profitability and strategic portfolio management, despite inherent risks.
Investment Thesis
Investing in Assertio Holdings presents a compelling opportunity due to its focus on niche pharmaceutical products with established market presence. The company's strategy of acquiring and revitalizing mature brands in neurology, hospital, and pain/inflammation offers a pathway to profitability. With a market capitalization of $0.08 billion, Assertio's potential for growth lies in its ability to optimize sales and marketing efforts for existing products. Key value drivers include effective lifecycle management of drugs like INDOCIN and CAMBIA, and strategic acquisitions of complementary products. Upcoming catalysts include potential new partnerships or licensing agreements to expand their product portfolio. While the company currently has a negative P/E ratio of -2.83 and a negative profit margin of -21.1%, successful execution of their strategy could lead to improved financial performance and increased shareholder value.
Key Highlights
- Market capitalization of $0.08 billion indicates a small-cap company with potential for high growth but also higher risk.
- Gross Margin of 68.2% demonstrates strong pricing power and efficient cost management in their product portfolio.
- Beta of 0.73 suggests lower volatility compared to the overall market, potentially offering a more stable investment.
- Focus on neurology, hospital, and pain/inflammation provides a targeted approach within the broader pharmaceutical industry.
- No dividend yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.
Competitors
Strengths
- Established product portfolio.
- Specialized expertise in niche therapeutic areas.
- High gross margin (68.2%).
- Experienced management team.
Weaknesses
- Small market capitalization ($0.08 billion).
- Negative P/E ratio (-2.83).
- Negative profit margin (-21.1%).
- Limited financial resources.
Catalysts
- Upcoming: Potential new partnerships or licensing agreements to expand product portfolio.
- Ongoing: Optimization of sales and marketing efforts for existing products.
- Ongoing: Active evaluation of potential acquisition targets.
- Upcoming: Results from ongoing research and development efforts on new formulations.
Risks
- Potential: Intense competition from larger pharmaceutical companies with greater resources.
- Ongoing: Regulatory risks and potential delays in product approvals.
- Ongoing: Pricing pressures from payers and potential changes in reimbursement policies.
- Potential: Product liability claims and potential recalls.
- Ongoing: Reliance on a limited number of products for revenue generation.
Growth Opportunities
- Expanding the Market Reach of Existing Products: Assertio can increase revenue by expanding the market reach of its existing products like INDOCIN and CAMBIA. This involves targeting new patient populations, exploring international markets, and developing new formulations or delivery methods. The market for pain management and neurology drugs is substantial, with a potential market size in the billions of dollars. Timeline: Ongoing, with continuous efforts to optimize marketing and sales strategies.
- Strategic Acquisitions of Complementary Products: Assertio can acquire complementary products or companies to expand its portfolio and diversify its revenue streams. This includes targeting drugs in similar therapeutic areas or acquiring companies with established sales and marketing infrastructure. The market for specialty pharmaceuticals is highly fragmented, with numerous opportunities for consolidation. Timeline: Ongoing, with active evaluation of potential acquisition targets.
- Developing New Formulations or Delivery Methods: Assertio can develop new formulations or delivery methods for its existing products to improve patient compliance, enhance efficacy, and extend product lifecycles. This includes exploring controlled-release formulations, transdermal patches, or injectable formulations. The market for innovative drug delivery systems is growing rapidly, driven by the demand for more convenient and patient-friendly treatments. Timeline: 2-3 years, with ongoing research and development efforts.
- Establishing Strategic Partnerships or Licensing Agreements: Assertio can establish strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop, co-market, or distribute its products. This allows Assertio to leverage the resources and expertise of its partners to accelerate growth and expand its market reach. The market for pharmaceutical partnerships is highly active, with numerous opportunities for collaboration. Timeline: Ongoing, with active engagement in business development activities.
- Optimizing Pricing and Reimbursement Strategies: Assertio can optimize its pricing and reimbursement strategies to maximize revenue and profitability. This includes negotiating favorable reimbursement rates with payers, implementing value-based pricing models, and offering patient assistance programs. The market for pharmaceuticals is highly price-sensitive, with increasing pressure from payers to control costs. Timeline: Ongoing, with continuous monitoring of market dynamics and payer policies.
Opportunities
- Strategic acquisitions of complementary products.
- Expansion into new markets.
- Development of new formulations and delivery methods.
- Strategic partnerships and licensing agreements.
Threats
- Intense competition from larger pharmaceutical companies.
- Regulatory risks and patent expirations.
- Pricing pressures from payers.
- Product liability claims.
Competitive Advantages
- Established product portfolio with recognized brand names.
- Specialized expertise in neurology, hospital, and pain/inflammation areas.
- Proprietary formulations and delivery methods.
- Existing relationships with healthcare providers and payers.
About
Assertio Holdings, Inc., established in 1995 and headquartered in Lake Forest, Illinois, is a specialty pharmaceutical company dedicated to providing treatments in neurology, hospital, and pain and inflammation areas. Originally known as Assertio Therapeutics, Inc., the company rebranded in May 2020 to Assertio Holdings, Inc. Assertio focuses on acquiring, developing, and commercializing differentiated pharmaceutical products. Their portfolio includes INDOCIN, available in oral solution and suppository form, targeting moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. CAMBIA, a non-steroidal anti-inflammatory drug (NSAID), addresses migraine symptoms like nausea, photophobia, and phonophobia. Zipsor provides relief for mild to moderate acute pain, while SPRIX is indicated for short-term management of moderate to moderately severe pain. Otrexup, an auto-injector containing methotrexate, treats adults with severe, active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. Assertio's strategy centers on maximizing the value of established products through focused promotion and lifecycle management, aiming to deliver consistent profitability and shareholder value.
What They Do
- Develop and market specialty pharmaceutical products.
- Focus on treatments for neurology, hospital, and pain/inflammation areas.
- Offer INDOCIN for rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis.
- Provide CAMBIA for migraine treatment.
- Market Zipsor for mild to moderate acute pain relief.
- Offer SPRIX for short-term management of moderate to moderately severe pain.
- Provide Otrexup for rheumatoid arthritis and juvenile idiopathic arthritis.
Business Model
- Acquire and commercialize established pharmaceutical products.
- Focus on niche markets and specific therapeutic areas.
- Implement lifecycle management strategies to maximize product value.
- Generate revenue through product sales and licensing agreements.
Industry Context
Assertio Holdings operates within the specialty pharmaceutical sector, which focuses on niche markets and specific therapeutic areas. The industry is characterized by intense competition, regulatory scrutiny, and the constant need for innovation. Companies like Assertio compete with both larger pharmaceutical firms and smaller, specialized players. The market for pain management and neurology drugs is substantial, driven by an aging population and increasing prevalence of chronic conditions. Assertio's strategy of acquiring and revitalizing established brands allows it to compete effectively by focusing on product lifecycle management and targeted marketing.
Key Customers
- Patients suffering from rheumatoid arthritis, migraines, and acute pain.
- Hospitals and healthcare providers.
- Pharmacies and distributors.
- Payers and insurance companies.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $49M | $11M | $0.00 |
| Q2 2025 | $29M | -$16M | $0.00 |
| Q1 2025 | $26M | -$14M | $0.00 |
| Q4 2024 | $32M | -$10M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Assertio Holdings, Inc. (ASRT) stock price: $0.82 (-0.04, -5.20%)
Why Bull
- •Recent insider buying signals confidence, suggesting those with inside knowledge believe the stock is undervalued.
- •Positive community sentiment indicates growing belief in the company's long-term strategy and execution.
- •A shift in market perception towards the company's sector could boost investor interest and drive demand.
- •Recent developments, such as successful product launches or positive clinical trial updates (if any), may be contributing to bullish sentiment.
Why Bear
- •Increased short interest suggests skepticism about the company's ability to meet expectations.
- •Negative community sentiment stemming from recent news or events could indicate waning confidence.
- •Market perception of the company's sector is currently unfavorable, potentially limiting upside potential.
- •Recent insider selling could signal concerns about the company's future prospects, despite any insider buying.
Latest News
-
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status
Yahoo! Finance: ASRT News · Feb 10, 2026
-
What Could Shift The Assertio Holdings ASRT Narrative After Recent Updates And Peer Signals
Yahoo! Finance: ASRT News · Feb 7, 2026
-
What Could Shift The Assertio Holdings ASRT Narrative After Recent Updates And Peer Signals
Simply Wall St. · Feb 7, 2026
-
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
Yahoo! Finance: ASRT News · Feb 5, 2026
Technical Analysis
Rationale
AI-generated technical analysis for ASRT including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Assertio Holdings, Inc. (ASRT) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for ASRT.
Make a Prediction
Set your price target for Assertio Holdings, Inc. (ASRT), choose a timeframe, and track your prediction accuracy.
Current price: $0.82
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASRT.
Price Targets
Wall Street price target analysis for ASRT.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -17.8% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 10/100
Gross margin of 65.5% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
News sentiment is mixed, with a balance of positive and negative coverage in recent days.
What does this score mean?
The MoonshotScore rates ASRT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status
What Could Shift The Assertio Holdings ASRT Narrative After Recent Updates And Peer Signals
What Could Shift The Assertio Holdings ASRT Narrative After Recent Updates And Peer Signals
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
Frequently Asked Questions
What does Assertio Holdings, Inc. do?
Assertio Holdings, Inc. is a specialty pharmaceutical company that focuses on acquiring, developing, and commercializing pharmaceutical products in the areas of neurology, hospital, and pain and inflammation. They market a portfolio of branded products, including INDOCIN for arthritis, CAMBIA for migraines, Zipsor for acute pain, SPRIX for moderate to severe pain, and Otrexup for rheumatoid arthritis. The company's business model centers around maximizing the value of established products through focused promotion and lifecycle management, aiming to deliver consistent profitability and shareholder value in niche pharmaceutical markets.
Is ASRT stock a good buy?
ASRT stock presents a mixed investment profile. The company's high gross margin of 68.2% suggests strong pricing power, but its negative P/E ratio and profit margin indicate current financial challenges. ASRT's focus on niche pharmaceutical products and strategic acquisitions could drive future growth, but investors should carefully consider the company's small market capitalization and competitive landscape. Potential investors should weigh the risks and opportunities carefully, considering their own risk tolerance and investment objectives before investing.
What are the main risks for ASRT?
The main risks for Assertio Holdings include intense competition from larger pharmaceutical companies, regulatory risks associated with drug approvals and patent expirations, and pricing pressures from payers and insurance companies. The company's reliance on a limited number of products for revenue generation also poses a risk. Additionally, potential product liability claims and recalls could negatively impact the company's financial performance and reputation. Investors should be aware of these risks before investing in ASRT.
Is ASRT a good stock to buy?
Whether ASRT is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the ASRT MoonshotScore?
The MoonshotScore for ASRT is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is ASRT data updated?
ASRT stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ASRT is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for ASRT?
Growth catalysts for Assertio Holdings, Inc. (ASRT) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Assertio Holdings, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are ASRT's main competitors?
Assertio Holdings, Inc. (ASRT) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ASRT has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about ASRT?
Wall Street analyst coverage for ASRT includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is ASRT's market cap?
Market capitalization (market cap) for ASRT is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ASRT's current market cap alongside enterprise value and other valuation metrics.
How has ASRT stock performed recently?
ASRT's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ASRT's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in ASRT?
Key risk categories for ASRT include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ASRT's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling ASRT?
Insider trading activity for ASRT tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is ASRT a good stock for beginners?
Assertio Holdings, Inc. (ASRT) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is ASRT for first-time investors?
Every stock carries risk, including Assertio Holdings, Inc. (ASRT). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ASRT.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change. Investment decisions should be based on thorough research and consultation with a financial advisor.